Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Oragenics Inc (NY: OGEN )

1.487 +0.107 (+7.75%)
Streaming Delayed Price Updated: 11:03 AM EDT, May 10, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Oragenics Inc

< Previous 1 2 Next >
Oragenics, Inc. Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards
From Oragenics, Inc.
Via Business Wire
Oragenics, Inc. Files 10K and Provides Company Update
From Oragenics, Inc.
Via Business Wire
Oragenics Appoints James Kelly MD, Chief Medical Officer, to Lead Phase II Clinical Trials for Treating Concussion
From Oragenics, Inc.
Via Business Wire
Oragenics, Inc. Prepares Drug for Phase II Clinical Trials to Treat Concussion
From Oragenics, Inc.
Via Business Wire
Oragenics Announces Closing of Public Offering
From Oragenics, Inc.
Via Business Wire
Oragenics Announces Pricing of Public Offering
From Oragenics, Inc.
Via Business Wire
Oragenics Announces Proposed Public Offering
From Oragenics, Inc.
Via Business Wire
Oragenics, Inc. Announces Leadership Transition
From Oragenics, Inc.
Via Business Wire
Oragenics, Inc. Announces Expiration of Its Investment Banking Engagement Agreement
From Oragenics, Inc.
Via Business Wire
Oragenics, Inc. Preparing for Phase II Clinical Trials to Treat Concussion
From Oragenics, Inc.
Via Business Wire
Oragenics Announces Termination of At-The-Market Offering Program
From Oragenics, Inc.
Via Business Wire
Oragenics Completes Acquisition of Odyssey Health’s Neurological Assets
From Oragenics, Inc.
Via Business Wire
Oragenics Issues Update to Shareholders
From Oragenics
Via Business Wire
Oragenics Announces Appointment of Bruce Cassidy and John Gandolfo to Board of Directors
From Oragenics, Inc.
Via Business Wire
Oragenics to Acquire Odyssey Health’s Neurological Drug Technology Pipeline Including Concussion Drug Candidate
From Oragenics, Inc.
Via Business Wire
Oragenics Enters into Agreement with Lantern Bioworks for Replacement-Therapy Assets
From Oragenics, Inc.
Via Business Wire
Oragenics, Inc. Announces Private Placement
From Oragenics, Inc.
Via Business Wire
Oragenics Project to Develop a Variant-Agnostic Protein Antigen for Use in its COVID-19 Intranasal Vaccine Receives Funding from CQDM
From Oragenics, Inc.
Via Business Wire
Oragenics to Participate in the World Vaccine Congress Washington
From Oragenics, Inc.
Via Business Wire
Oragenics Announces Positive Results in Several Lantibiotics Compounds Against MRSA and VRE
From Oragenics, Inc.
Via Business Wire
Oragenics Appoints Janet Huffman as Chief Financial Officer Strengthening Executive Leadership Team
From Oragenics, Inc.
Via Business Wire
Oragenics Enters into an Exclusive Global License Agreement with Inspirevax to Develop Intranasal Covid Vaccine Candidate
From Oragenics, Inc.
Via Business Wire
Oragenics, Inc. Regains Compliance with NYSE American
From Oragenics, Inc.
Via Business Wire
Oragenics, Inc. Discloses One-for-Sixty Reverse Stock Split
From Oragenics, Inc.
Via Business Wire
Oragenics Reports Favorable Toxicology Results for its COVID-19 Intranasal Vaccine Candidate
From Oragenics, Inc.
Via Business Wire
Oragenics, Inc. Receives NYSE American Notice
From Oragenics, Inc.
Via Business Wire
Oragenics, Inc. Announces New Chair
From Oragenics, Inc.
Via Business Wire
Oragenics to Participate in the 2022 BioFlorida Annual Conference
From Oragenics, Inc.
Via Business Wire
Oragenics Issues Letter to Shareholders
From Oragenics, Inc.
Via Business Wire
Oragenics Announces Favorable Preliminary Toxicology Data for Intranasal COVID-19 Vaccine Candidate
From Oragenics, Inc.
Via Business Wire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.